Autobio(SH:603658)2021-04-22 16:00Financial Performance - The company's operating revenue for 2020 was CNY 2,978,131,605.36, representing an increase of 11.15% compared to CNY 2,679,435,637.43 in 2019[17]. - The net profit attributable to shareholders for 2020 was CNY 747,793,833.41, a decrease of 3.41% from CNY 774,163,957.63 in 2019[17]. - The net cash flow from operating activities increased by 18.01% to CNY 994,713,153.79 in 2020, up from CNY 842,886,756.83 in 2019[17]. - The total assets at the end of 2020 were CNY 8,137,141,424.06, reflecting a growth of 91.15% compared to CNY 4,256,869,652.23 at the end of 2019[17]. - The net assets attributable to shareholders increased by 153.33% to CNY 6,477,364,992.31 at the end of 2020, compared to CNY 2,556,920,911.58 at the end of 2019[17]. - The basic earnings per share for 2020 were CNY 1.74, down 5.43% from CNY 1.84 in 2019[18]. - The weighted average return on equity for 2020 was 22.13%, a decrease of 12.68 percentage points from 34.81% in 2019[18]. - The company achieved a revenue of 2.978 billion yuan in 2020, representing a year-on-year growth of 11.15%[60]. - The net profit attributable to shareholders was 748 million yuan, a decrease of 3.41% compared to the previous year[60]. Dividend Policy - The company plans to distribute a cash dividend of 8.5 RMB per 10 shares, totaling approximately 383.33 million RMB, which accounts for 51.26% of the net profit attributable to shareholders[4]. - The company plans to prioritize cash dividends in its profit distribution policy for the next three years (2020-2022) to ensure stable returns for investors[111]. - The company aims to maintain a minimum cash dividend ratio of 20% of the distributable profit each year, with higher ratios depending on the company's development stage and capital expenditure plans[112]. - The company has established a sustainable profit distribution policy that considers factors such as operational performance, shareholder expectations, and external financing conditions[111]. - The company’s cash dividend distribution in 2019 was 9.0 CNY per 10 shares, totaling approximately 387.54 million CNY, which accounted for 50.06% of the net profit attributable to ordinary shareholders[114]. Research and Development - The company is focused on enhancing its research and development capabilities to drive innovation in its product offerings[1]. - R&D investments from 2018 to 2020 were CNY 216.68 million, CNY 311.91 million, and CNY 346.37 million, representing 11.23%, 11.64%, and 11.63% of revenue respectively[43]. - The company has obtained 557 patents, including 39 international patents, and registered 528 products, with 322 receiving EU CE certification[44]. - The company has developed a diagnostic antibody library targeting 24,100 antigen epitopes, achieving a self-sufficiency rate of over 75.8% for registered immunodiagnostic reagents[45]. - The company is focusing on the development of intelligent laboratory solutions to meet the increasing automation and information technology demands in medical laboratories[62]. - The company plans to enhance its R&D capabilities in molecular diagnostics, immunodiagnostics, and biochemical diagnostics[100]. - The company is investing heavily in R&D, allocating 10% of its revenue, approximately 150 million RMB, towards new technology development[188]. Market Expansion and Strategy - The company plans to continue expanding its market presence and invest in new product development[1]. - The company is actively involved in the development of new technologies and products to enhance its market position[82]. - Market expansion plans include entering three new provinces, aiming for a 10% market share in these regions within the next two years[189]. - The company is considering strategic acquisitions to enhance its product portfolio, targeting companies with complementary technologies[187]. - The company has established partnerships with two major healthcare providers to enhance distribution channels[189]. Compliance and Audit - The company has received a standard unqualified audit report from Zhongqin Wanxin Accounting Firm[3]. - The company appointed Zhongqin Wanxin Accounting Firm as its auditor for the 2020 financial year, with an audit fee of RMB 550,000[123]. - The company’s internal control audit was also conducted by Zhongqin Wanxin Accounting Firm, with a fee of RMB 200,000[123]. - The company has not faced any risks of suspension or termination of listing during the reporting period[120]. Environmental Responsibility - The average COD discharge concentration was 31 mg/L, with a total COD discharge of 2.57 tons in 2020, which is within the regulatory limits[146]. - The company has a wastewater treatment facility with a capacity of 500 m³/d to ensure compliance with discharge standards[147]. - The company has installed three sets of electrostatic oil smoke separators to ensure that oil smoke emissions meet regulatory requirements[147]. - The company has passed the ISO14001 environmental management system certification, indicating a commitment to environmental protection[151]. - The company has not reported any instances of exceeding pollution discharge limits in its environmental monitoring[146]. Shareholder Information - The total number of ordinary shareholders decreased from 18,644 to 13,146 during the reporting period[168]. - The company’s total share capital increased from 420,000,000 shares to 450,978,659 shares after the issuance of new shares[167]. - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 248,633,287 shares, representing 55.13% of the total shares[169]. - The actual controller of the company is Miao Yongjun, who is also the chairman of the board[178]. - The total number of shares held by the chairman, Miao Yongjun, decreased from 96,785,235 to 94,834,106, a reduction of 1,951,129 shares, attributed to the indirect reduction by Antu Industrial[184]. Legal Matters - The company received a lawsuit from Bai Xianhe, demanding a distribution of 1.1887% of shares (4,992,714.216 shares) or a payment of 80 million RMB if shares could not be allocated[125]. - The court ruled on May 20, 2020, that Bai Xianhe's request for equity incentive was unsupported by evidence and dismissed the claim[125]. Financial Management - The company has engaged in cash asset management, with a total of 2,692,120,000 RMB from self-owned funds and 4,829,000,000 RMB from raised funds in bank wealth management products[133]. - The company reported a total return of 7,302,847.22 CNY from financial products purchased in 2019[135]. - The average return on investments in financial products was approximately 3.5% during the reporting period[135]. - The company plans to continue expanding its investment in financial products, with a focus on high-yield opportunities[136].